#Semaglutide 2Β·4 mg once a week in adults with #overweight or #obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Background This trial assessed the efficacy and safety of the GLP-1 analogue once a week subcutaneous semaglutide 2Β·4 mg versus semaglutide 1Β·0 mg (the dose approved for diabetes treatment) and placebo for weight management in adults with overweight or obesity, and type 2 diabetes. Methods This double-blind, double-dummy, phase 3, superiority study enrolled adults with a body-mass index of at least 27 kg/m2 and glycated … Continue reading #Semaglutide 2Β·4 mg once a week in adults with #overweight or #obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Rate This

The Value of Total #Knee Replacement in Patients With Knee #Osteoarthritis and a Body Mass Index of 40 kg/m2 or Greater A Cost-Effectiveness Analysis

Total knee replacement (TKR) is an effective and cost-effective strategy for treating end-stage knee osteoarthritis. Greater risk for complications among TKR recipients with a body mass index (BMI) of 40 kg/m2 or greater has raised concerns about the value of TKR in this population. Objective: To assess the value of TKR in recipients with a BMI of 40 kg/m2 or greater using a cost-effectiveness analysis. … Continue reading The Value of Total #Knee Replacement in Patients With Knee #Osteoarthritis and a Body Mass Index of 40 kg/m2 or Greater A Cost-Effectiveness Analysis

Rate This